DRI Capital is marketing a $220 million securitization of 18 drug royalty streams generated from the global sales of 11 drugs.

The deal, called Series 2012-2 is the second deal for DRI Capital this year, according to Moody’s Investors Service. The ratings agency rated both the earlier March deal and the issuer’s latest deal.  

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.